<DOC>
	<DOCNO>NCT00963521</DOCNO>
	<brief_summary>RATIONALE : Vaccines make dendritic cell may help body build effective immune response kill cancer cell . PURPOSE : This phase I trial study side effect vaccine therapy see well work treat patient acute myeloid leukemia complete remission .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Acute Myeloid Leukemia Complete Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess tolerability autologous dendritic cell vaccine patient acute myelogenous leukemia complete remission . Secondary - Evaluate emergence immune response . - Determine relapse rate . - Assess occurrence residual disease . OUTLINE : Patients receive increase dos blastic cell transform vitro autologous dendritic cell ( 1/3 subcutaneously 2/3 IV ) every 3 week 5 dos .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myelogenous leukemia ( AML ) Myelomonocytic ( M4 ) monocytic ( M5 ) subtype In second complete remission ( CR ) later follow CR1 last ≤ 12 month chemotherapy may include intensification regimen follow autologous transplantation No ( 15 ; 17 ) translocation No AML M3 HLAA2 positivity CD14 ≥ 20 % peripheral blood mononuclear cell Circulating blast ≥ 10 x 109/L ( collect prior chemotherapy ) available Must eligible HLAmatched allogeneic transplantation No progressive disease PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Not pregnant nursing Fertile patient must use effective contraception No contraindication cytopheresis chemotherapy No HIV HTLV positivity No hepatitis B C activation No prior psychological disease Not deprive liberty able give consent Must able speak read French No cancer except basal cell cervical PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
</DOC>